Europe Active Pharmaceutical Ingredients Market – Industry Analysis and Forecast (2017-2026) _ by Synthesis Type, by Drug Type, by Manufacturer Type, by Therapeutic Area, and by Geography

Europe Active Pharmaceutical Ingredients Market – Industry Analysis and Forecast (2017-2026) _ by Synthesis Type, by Drug Type, by Manufacturer Type, by Therapeutic Area, and by Geography

Market Scenario

Europe Active Pharmaceutical Ingredients Market is expected to reach USD 70.0 billion by 2026 from USD 36.7 Billion in 2016 at a CAGR of 6.7% (Detailed analysis of the market CAGR is provided in the report). The active pharmaceutical ingredient is the drug component which is responsible for producing the medicinal effects on patients. API or active pharmaceutical ingredient and excipient are two key components for drug that are used by manufacturers. Combination therapies are used by certain drugs that include multiple active ingredients for treatment of illness symptoms. API forms the central ingredient while the excipient is the substance that covers API and is used for delivering medication inside the human body system. Excipients re chemically inactive substances by composition and do not react with the API. Pharmaceutical companies that are into manufacturing of drugs use certain pre-notified standards for determining the API strength of each drug. The standard may vary broadly from one brand to another as companies use different tests manufacturing drugs. Europe Active Pharmaceutical Ingredients Market Europe active pharmaceuticals market is segmented into drug type, manufacturer type, synthesis type, therapeutic area, and geography. Considering the synthesis type segment, the market for active pharmaceuticals is divided into biotech and synthetic. High R&D for novel biosimilar drugs and the shift in focus of traditional manufacturers towards biological drugs resulted in biotech segment holding the largest segment. On the basis of drug type, the market has been divided into branded drugs, generic drugs, and over-the-counter (OTC) drugs. Higher spending on R&D activities together with the rise in drug prices have resulted in branded drugs holding the largest segment and has a huge scope of growth as well. By manufacturer type, the market diverges into merchant and captive manufacturers as merchant manufacturers have held one of the fastest growing. A rise in outsourcing of drug molecule formulation by drug manufacturers is a major factor that has boosted the growth of merchant manufacturer segment. In addition, drug manufacturers are choosing outsourcing options for eliminating the need of heavy investment in their manufacturing process. This has acted as another major factor to boost the high growth of merchant manufacturers in Europe. Europe is very strict about its medical facilities and rules. This has resulted in manufacturers becoming more stringent about the active pharmaceutical ingredients. Presence of some large pharmaceutical companies that manufacture drugs has resulted in market growth for active pharmaceutical ingredients in Europe. UK, Germany, and France are a few major countries that have resulted in higher demand for API and boosted the overall market growth. Key Highlights: • Europe Active Pharmaceutical Ingredients market size analysis and forecast • Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the Europe Active Pharmaceutical Ingredients Market • Europe Active Pharmaceutical Ingredients Market segmentation on the basis of synthesis type, drug type, manufacturer type, therapeutic area and geography. • Europe Active Pharmaceutical Ingredients Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of the study • Europe Active Pharmaceutical Ingredients Market analysis and forecast for major countries has been provided. • Profiling of key industry players, their strategic perspective, market positioning and analysis of core competencies • Competitive landscape of the key players operating in the Active Pharmaceutical Ingredients market including competitive developments, investments, and strategic expansion Years that have been considered for the study are as follows: • Base Year – 2016 • Estimated Year – 2017 • Forecast Period – 2017 to 2026 For company profiles, 2016 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered. Research Methodology: The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at a market value for Europe Active Pharmaceutical Ingredients market. Some of the key players in the Europe Active Pharmaceutical Ingredients market include: • Boehringer Ingelheim GmbH • Merck • Abbvie • Sun Pharmaceuticals • Dr. Reddy’s Laboratories • Albemarle Corporation • Bristol-Myers Squibb Company • Eli Lily and Company • Vinchem • Corden Pharma Key Target Audience: • Healthcare companies • Corporate healthcare entities • Government agencies • Market research and consulting firms • Venture capitalists • Technical Students Scope of the Report: The research report segments Europe Active Pharmaceutical Ingredients market based on synthesis type, drug type, manufacturer type, therapeutic area and geography. Active Pharmaceutical Ingredients Market, By Synthesis Type: • Biotech • Monoclonal Antibodies • Recombinant Proteins • Vaccines • Synthetic Active Pharmaceutical Ingredients Market, By Drug Type: • Branded Drugs • Generic Drugs • Over-the-counter (OTC) Drugs Active Pharmaceutical Ingredients Market, By Manufacturer Type: • Captive Manufacturers • Merchant Manufacturers Active Pharmaceutical Ingredients Market, By Therapeutic Area: • Cardiology • Pulmonology • Oncology • Neurology • Ophthalmology • Orthopedics • Others Active Pharmaceutical Ingredients Market, By Geography: • Europe • UK • Germany • Italy • France • Russia • Spain • Others Geographic Analysis: • Breakdown of UK Active Pharmaceutical Ingredients Market • Breakdown of Germany Active Pharmaceutical Ingredients Market • Breakdown of Italy Active Pharmaceutical Ingredients Market • Breakdown of France Active Pharmaceutical Ingredients Market • Breakdown of Russia Active Pharmaceutical Ingredients Market • Breakdown of Spain Active Pharmaceutical Ingredients Market • Breakdown of Others Active Pharmaceutical Ingredients Market Available Customizations: Maximize Market Research offers customizations of reports according to the specific requirement of our clients Middle-East Ventilator Market: Industry Analysis and Forecast 2026

Table of Contents

1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET VARIABLES & SCOPE 3.1. Market Segmentation & Scope 3.2. Market Driver Analysis 3.3. Market Restraint Analysis 3.4. Penetration &Growth Prospect Mapping 3.5. Market SWOT Analysis, By Factor (political & legal, economic and technological) 3.6. Porter’s Five Forces Industry Analysis 3.7. Market Value Chain Analysis 4. SYNTHESIS TYPE ESTIMATES & TREND ANALYSIS (2016 – 2026) 4.1. Active Pharmaceutical Ingredients Market: Synthesis Type Movement Analysis 4.2. Biotech 4.2.1. Biotech market, 2016 – 2026 (USD billion) 4.2.2. Monoclonal antibodies 4.2.2.1. Monoclonal antibodies market, 2016 – 2026 (USD billion) 4.2.3. Recombinant proteins 4.2.3.1. Recombinant proteins market, 2016 – 2026 (USD billion) 4.2.4. Vaccines 4.2.4.1. Vaccines market, 2016 – 2026 (USD billion) 4.3. Synthetic 4.3.1. Synthetic market, 2016 – 2026 (USD billion) 5. DRUG TYPE ESTIMATES & TREND ANALYSIS (2016 – 2026) 5.1. Active Pharmaceutical Ingredients Market: Drug Type Movement Analysis 5.2. Branded/Innovative Drugs 5.2.1. Branded/Innovative drugs market, 2016 – 2026 (USD billion) 5.3. Generic Drugs 5.3.1. Generic drugs market, 2016 – 2026 (USD billion) 5.4. Over-the-counter (OTC) Drugs 5.4.1. Over-the-counter market, 2016 – 2026 (USD billion) 6. MANUFACTURER TYPE ESTIMATES & TREND ANALYSIS (2016 – 2026) 6.1. Active Pharmaceutical Ingredients Market: Manufacturer Type Movement Analysis 6.2. Captive Manufacturers 6.2.1. Captive manufacturers market, 2016 – 2026 (USD billion) 6.3. Merchant Manufacturers 6.3.1. Merchant manufacturers market, 2016 – 2026 (USD billion) 7. THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS (2016 – 2026) 7.1. Active Pharmaceutical Ingredients Market: Therapeutic Area Movement Analysis 7.2. Cardiology 7.2.1. Cardiology market, 2016 – 2026 (USD billion) 7.3. Pulmonology 7.3.1. Pulmonology market, 2016 – 2026 (USD billion) 7.4. Oncology 7.4.1. Oncology market, 2016 – 2026 (USD billion) 7.5. Neurology 7.5.1. Neurology market, 2016 – 2026 (USD billion) 7.6. Ophthalmology 7.6.1. Ophthalmology market, 2016 – 2026 (USD billion) 7.7. Orthopedics 7.7.1. Orthopedics market, 2016 – 2026 (USD billion) 7.8. Others 7.8.1. Others market, 2016 – 2026 (USD billion) 8. REGIONAL ESTIMATES & TREND ANALYSIS BY SYNTHESIS TYPE, DRUG TYPE, MANUFACTURER TYPE, AND THERAPEUTIC AREA (2016 – 2026) 8.1. Active Pharmaceutical Ingredients Market Share By Region, 2016 & 2026 8.2. Europe 8.2.1. Europe active pharmaceutical ingredients market, 2016 – 2026 (USD billion) 8.2.2. UK 8.2.2.1. UK Active Pharmaceutical Ingredients market, 2016 – 2026 (USD billion) 8.2.3. Germany 8.2.3.1. Germany Active Pharmaceutical Ingredients market, 2016 – 2026 (USD billion) 8.2.4. Russia 8.2.4.1. Russia Active Pharmaceutical Ingredients market, 2016 – 2026 (USD billion) 8.2.5. France 8.2.5.1. France Active Pharmaceutical Ingredients market, 2016 – 2026 (USD billion) 8.2.6. Spain 8.2.6.1. Spain Active Pharmaceutical Ingredients market, 2016 – 2026 (USD billion) 8.2.7. Italy 8.2.7.1. Italy Active Pharmaceutical Ingredients market, 2016 – 2026 (USD billion) 8.2.8. Others 8.2.8.1. Others Active Pharmaceutical Ingredients market, 2016 – 2026 (USD billion) 9. MARKET COMPETITION ANALYSIS 9.1. Strategy Framework 9.2. Company Profiles 9.2.1. Eli Lily and Company 9.2.1.1. Company Overview 9.2.1.2. Financial Performance 9.2.1.3. Product Benchmarking 9.2.1.4. Strategic Initiatives 9.2.2. Corden Pharma 9.2.2.1. Company Overview 9.2.2.2. Financial Performance 9.2.2.3. Product Benchmarking 9.2.2.4. Strategic Initiatives 9.2.3. Boehringer Ingelheim GmbH 9.2.3.1. Company Overview 9.2.3.2. Financial Performance 9.2.3.3. Product Benchmarking 9.2.3.4. Strategic Initiatives 9.2.4. Merck & Co., Inc. 9.2.4.1. Company Overview 9.2.4.2. Financial Performance 9.2.4.3. Product Benchmarking 9.2.4.4. Strategic Initiatives 9.2.5. Abbvie 9.2.5.1. Company Overview 9.2.5.2. Financial Performance 9.2.5.3. Product Benchmarking 9.2.5.4. Strategic Initiatives 9.2.6. Vinchem 9.2.6.1. Company Overview 9.2.6.2. Financial Performance 9.2.6.3. Product Benchmarking 9.2.6.4. Strategic Initiatives 9.2.7. Sun Pharmaceuticals 9.2.7.1. Company Overview 9.2.7.2. Financial Performance 9.2.7.3. Product Benchmarking 9.2.7.4. Strategic Initiatives 9.2.8. Albemarle Corporation 9.2.8.1. Company Overview 9.2.8.2. Financial Performance 9.2.8.3. Product Benchmarking 9.2.8.4. Strategic Initiatives 9.2.9. Dr. Reddy’s Laboratories 9.2.9.1. Company Overview 9.2.9.2. Financial Performance 9.2.9.3. Product Benchmarking 9.2.9.4. Strategic Initiatives 9.2.10. Bristol-Myers Squibb Company 9.2.10.1. Company Overview 9.2.10.2. Financial Performance 9.2.10.3. Product Benchmarking 9.2.10.4. Strategic Initiatives

Inquiry Before Buying

Request Sample

About This Report

Report ID 2141
Published Date
Contact Us
Call Now